| Date | Title | | | 06/03/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009| SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual Needham Life
Sciences Conference on Wednesday, June 10, 2009 at 9:30 a.m. Eastern
Time at The New York Palace Hotel in New York City.
... |
|  | | 05/13/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009| SAN DIEGO--(BUSINESS WIRE)--May. 13, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual JMP Securities
Research Conference on Tuesday, May 19, 2009 at 2:30 p.m. Pacific Time
at The Ritz-Carlton Hotel in San Francisco.
... |
| | | 05/11/09 | ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 11, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the first quarter
ended March 31, 2009.
ACADIA reported a net loss of $15.0 million, or $0.40 per common share,
for the first quarter ... |
| | | 05/06/09 | ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| Top-Line Data Expected in the Third Quarter of 2009
SAN DIEGO & TORONTO--(BUSINESS WIRE)--May. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Biovail Corporation
(NYSE:BVF) (TSX:BVF), today announced the completion of enrollment in
the first pivotal Phase III clinical trial of pimavanserin in patients
with Parkinson’s disease psychosis (PDP). Top-line results from this
trial are expected to be announced by the end of the third quarter of
20... |
| | | 05/05/09 | ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009| ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2009 on... |
| | | 05/04/09 | ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America| Conference Call Scheduled for Today, May 4, 2009, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it has
established a collaboration with Biovail Laboratories International SRL,
a subsidiary of Biovail Corporation, to co-develop and commercialize
pimavanserin, ACADIA’s proprietary and selective 5-HT2A inverse
agonist, in the United States and Canada. ACADIA retains rights t... |
| | | 03/25/09 | ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs| Meiji Seika Granted Rights to Develop and Commercialize Products in Asian Territory; ACADIA Retains All Rights in the Rest of the World
SAN DIEGO--(BUSINESS WIRE)--Mar. 25, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd.
(TSE:2202) today announced that they have established a collaboration to
develop and commercialize a novel class of pro-cognitive drugs to treat
patients with schizophrenia and related disorders in Japan and several
... |
| | | 03/09/09 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008| SAN DIEGO--(BUSINESS WIRE)--Mar. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter
and year ended December 31, 2008.
ACADIA reported a net loss of $14.0 million, or $0.38 per common share,
for the fo... |
| | | 03/04/09 | ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009| SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Barclays Capital Global
Healthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. Eastern
Time at the Loews Miami Beach Hotel in Miami Beach, Florida.... |
| | | 03/02/09 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009| ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended Decemb... |
| | | 02/03/09 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern
Time at The Waldorf=Astoria Hotel in New York City.
A live webcast o... |
| | | 01/07/09 | ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it has been awarded a grant from The Michael J. Fox
Foundation for the development of novel estrogen receptor beta (ER-beta)
agonists for the treatment of Parkinson’s disease. The grant of up to
... |
| |
|
